Detalhe da pesquisa
1.
PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.
Breast Cancer Res
; 25(1): 1, 2023 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36597146
2.
Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature.
Curr Oncol Rep
; 22(2): 15, 2020 02 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32025905
3.
Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial.
Clin Cancer Res
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38573708
4.
Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients.
Breast
; 67: 26-29, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36566691
5.
Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer.
J Am Heart Assoc
; 12(12): e029361, 2023 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37301767
6.
Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer.
Cell Rep Med
; 3(6): 100668, 2022 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35732147
7.
18F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer.
Radiol Imaging Cancer
; 4(6): e220032, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36269154
8.
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer.
NPJ Breast Cancer
; 8(1): 122, 2022 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36369506
9.
The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.
BJU Int
; 108(2 Pt 2): E84-90, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21050361
10.
Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
Clin Cancer Res
; 27(2): 371-373, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33144339
11.
Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms.
Cancers (Basel)
; 13(13)2021 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34209587
12.
Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma.
CNS Oncol
; 8(3): CNS43, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31769726
13.
Germline mutations in the alternative pathway of complement predispose to HELLP syndrome.
JCI Insight
; 3(6)2018 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29563339
14.
On the Rise of Cyclin-Dependent Kinase Inhibitors in Breast Cancer: Progress & Ongoing Challenges.
Breast Cancer Manag
; 9(2)2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34475968